Who We Are

Fosun has become a global innovation-driven consumer group

Fosun was founded in 1992. After more than 30 years of development, Fosun has become a global innovation-driven consumer group.
Adhering to the mission of creating happier lives for families worldwide, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of families worldwide in Health, Happiness and Wealth. In 2007, Fosun International Limited was listed on the main board of the Hong Kong Stock Exchange (stock code: 00656.HK). As of 31 December 2025, Fosun International’s total assets amounted to RMB716.2 billion, and its latest MSCI ESG rating is AAA.

  • 173.43

    Total revenue in 2025
    (RMB billion)

  • 716.2

    Total assets as at 31 December 2025
    (RMB billion)

  • AAA

    MSCI ESG rating

Mission

Creating happier lives for families worldwide

Vision

Rooted in China, creating a global happiness ecosystem fulfilling the needs of families worldwide in health, happiness and wealth

Values

Self-improvement, Teamwork, Performance and Contribution to Society

Milestones

Rooted in China, Fosun has been developing globally and has long adhered to the two core growth drivers of “innovation” and “globalization”. Fosun is one of the few Chinese companies that is equipped with global operation and investment capabilities, and has accumulated profound technology and innovation capabilities.

  • 1992

    Fosun was founded with a capital of RMB38,000

  • 1994

    Fosun Pharma
    Forte

  • 1998

    Listing of Fosun Pharma on the Shanghai Stock Exchange

  • 2002

    Yuyuan

  • 2003

    Sinopharm Group

  • 2007

    Hainan Mining Listing of Fosun International (00656.HK) on the Hong Kong Stock Exchange

  • 2010

    Club Med
    Henlius

  • 2011

    The Bund Finance Center (BFC)

  • 2012

    Pramerica Fosun Life Insurance、Peak Re、Starcastle Senior Living

  • 2013

    Atlantis Sanya Foshan Fosun Chancheng Hospital、Sisram Med

  • 2014

    Fidelidade
    Luz Saúde
    ROC

  • 2015

    Silver Cross
    Full acquisition of Club Med

  • 2016

    Gland Pharma、HAFS、Wolverhampton Wanderers F.C.、BabyTree、AHAVA

  • 2017

    Fosun United Health Insurance Intuitive Fosun Fosun Kairos

  • 2018

    LANVIN、Wolford、Songhelou、Listing of Fosun Tourism Group ("FTG") on the Hong Kong Stock Exchange

  • 2019

    FFT、Listing of Shanghai Henlius on the Hong Kong Stock Exchange

  • 2020

    DJULA、WEI、Shede Spirits

  • 2021

    Sergio Rossi、Wansheng

  • 2022

    Listing of Lanvin Group on the New York Stock Exchange、Yelanggujiu

  • 2023

    Overseas debut of Yuyuan Garden Lantern Festival

  • 2024

    Overseas launch of Henlius's HANQUYOU, HANSIZHUANG, HANLIKANG etc. Launch of the ULTRAMED Hainan project

  • 2025

    Fosun Pharma's out-licensing of YP05002 and other small molecule drugs

  • 1992

    Fosun was founded with a capital of RMB38,000

  • 1994

    Fosun Pharma
    Forte

  • 1998

    Listing of Fosun Pharma on the Shanghai Stock Exchange

  • 2002

    Yuyuan

  • 2003

    Sinopharm Group

  • 2007

    Hainan Mining Listing of Fosun International (00656.HK) on the Hong Kong Stock Exchange

  • 2010

    Club Med
    Henlius

  • 2011

    The Bund Finance Center (BFC)

  • 2012

    Pramerica Fosun Life Insurance、Peak Re、Starcastle Senior Living

  • 2013

    Atlantis Sanya Foshan Fosun Chancheng Hospital、Sisram Med

  • 2014

    Fidelidade
    Luz Saúde
    ROC

  • 2015

    Silver Cross
    Full acquisition of Club Med

  • 2016

    Gland Pharma、HAFS、Wolverhampton Wanderers F.C.、BabyTree、AHAVA

  • 2017

    Fosun United Health Insurance Intuitive Fosun Fosun Kairos

  • 2018

    LANVIN、Wolford、Songhelou、Listing of Fosun Tourism Group ("FTG") on the Hong Kong Stock Exchange

  • 2019

    FFT、Listing of Shanghai Henlius on the Hong Kong Stock Exchange

  • 2020

    DJULA、WEI、Shede Spirits

  • 2021

    Sergio Rossi、Wansheng

  • 2022

    Listing of Lanvin Group on the New York Stock Exchange、Yelanggujiu

  • 2023

    Overseas debut of Yuyuan Garden Lantern Festival

  • 2024

    Overseas launch of Henlius's HANQUYOU, HANSIZHUANG, HANLIKANG etc. Launch of the ULTRAMED Hainan project

  • 2025

    Fosun Pharma's out-licensing of YP05002 and other small molecule drugs

x

抖音二维码

扫一扫